Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

(18)F-fluoroestradiol Tumor Uptake is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans AWJM, de Vries EFJ, Bongaerts AHH, Schröder CP, de Vries EGE, Hospers GAP.

J Nucl Med. 2018 Mar 30. pii: jnumed.117.198846. doi: 10.2967/jnumed.117.198846. [Epub ahead of print]

PMID:
29602822
2.

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP.

J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14.

PMID:
28912144
3.

Hormone receptors as a marker of poor survival in epithelial ovarian cancer.

van Kruchten M, van der Marel P, de Munck L, Hollema H, Arts H, Timmer-Bosscha H, de Vries E, Hospers G, Reyners A.

Gynecol Oncol. 2015 Sep;138(3):634-9. doi: 10.1016/j.ygyno.2015.06.032. Epub 2015 Jun 24.

PMID:
26115976
4.

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

van Kruchten M, Glaudemans AWJM, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GAP.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1674-1681. doi: 10.1007/s00259-015-3107-5. Epub 2015 Jun 20.

5.

The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, Glaudemans AW, de Vries EF, de Vries EG, Hospers GA, de Bock GH.

Br J Cancer. 2015 May 12;112(10):1617-25. doi: 10.1038/bjc.2015.138. Epub 2015 Apr 16.

6.

Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.

van Kruchten M, de Vries EF, Arts HJ, Jager NM, Bongaerts AH, Glaudemans AW, Hollema H, de Vries EG, Hospers GA, Reyners AK.

J Nucl Med. 2015 Jan;56(1):50-5. doi: 10.2967/jnumed.114.147579. Epub 2014 Dec 4.

7.

Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.

Falahi F, van Kruchten M, Martinet N, Hospers GA, Rots MG.

Breast Cancer Res. 2014 Jul 29;16(4):412. doi: 10.1186/s13058-014-0412-z. Review.

8.

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, Brown M, Schröder CP, de Vries EF, Hospers GA.

Cancer Discov. 2015 Jan;5(1):72-81. doi: 10.1158/2159-8290.CD-14-0697. Epub 2014 Nov 7.

9.

Whole-body PET imaging of breast cancer characteristics to improve precision treatment.

Hospers GA, van Kruchten M, de Vries EG.

Oncology (Williston Park). 2014 May;28(5):434-6. No abstract available.

10.

PET imaging of oestrogen receptors in patients with breast cancer.

van Kruchten M, de Vries EGE, Brown M, de Vries EFJ, Glaudemans AWJM, Dierckx RAJO, Schröder CP, Hospers GAP.

Lancet Oncol. 2013 Oct;14(11):e465-e475. doi: 10.1016/S1470-2045(13)70292-4. Review.

PMID:
24079874
11.

Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature.

van Kruchten M, Hospers GA, Glaudemans AW, Hollema H, Arts HJ, Reyners AK.

Eur J Cancer. 2013 Dec;49(18):3850-5. doi: 10.1016/j.ejca.2013.08.005. Epub 2013 Sep 2. Review.

PMID:
24007820
12.

Molecular imaging for monitoring treatment response in breast cancer patients.

Bensch F, van Kruchten M, Lamberts LE, Schröder CP, Hospers GA, Brouwers AH, van Vugt MA, de Vries EG.

Eur J Pharmacol. 2013 Oct 5;717(1-3):2-11. doi: 10.1016/j.ejphar.2013.01.079. Epub 2013 Mar 30. Review.

PMID:
23545359
13.

PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.

van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, de Vries EG, Hospers GA.

J Nucl Med. 2012 Feb;53(2):182-90. doi: 10.2967/jnumed.111.092734. Epub 2012 Jan 12.

Supplemental Content

Loading ...
Support Center